ArticleTherapeutic advances in neurological disorders2026

Vedolizumab and the gut-CNS axis in multiple sclerosis: considering T cell licensing pathways.

Afsaneh Shirani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.